Meha Kabra, PhD, Division of Neonatology and Newborn Nursery, has been awarded a one-year Knights Templar Eye Foundation Career Starter Research Grant of $90,000 for a project called, “Therapeutic genome editing of the large CACNA1F gene for the treatment of congenital stationary night blindness type 2 (CSNB2).” CSNB2, congenital stationary night blindness, occurs due to mutations in the CACNA1F gene. This gene makes a protein subunit α1, which combines with other subunits (β and α2δ4) to form the complete multimeric ion channel, Cav1.4. This protein is essential in photoreceptors (PRs) to transmit the signal to bipolar cells. Currently, there is no cure for CSNB2. The present study is designed to generate tools to investigate the potential of genome editors (adenosine base editors, ABE, and prime editors; PE) for correcting the CACNA1F mutation in PRs and make the channel functional. When completed, the study will make a broad and sustained impact in the genome editing field and help us to develop optimal ABE and PE for other inherited retinal diseases affecting the PRs, evaluate the effectiveness and safety of future genome editing translations in the clinic, and establish an editing threshold required to rescue the CSNB2 phenotype. The award begins on July 1, 2025.